Uncategorized
Study to evaluate elamipretide for dry AMD
The ReCLAIM phase 1 study evaluating the use of elamipretide for intermediate age-related macular degeneration has been initiated, according to a press release from Stealth BioTherapeutics.The open-label study will evaluate elamipretide’s safety and tolerability through 12 weeks of treatment with daily subcutaneous injections, the release said. Patients will be age 55 years or older and have at least one eye with intermediate AMD, as well as either drusen on the retina without geographic atrophy or geographic atrophy with an unaffected central fovea.